Home Angiogenesis Target Protein Ligand chemical - BTK inhibitor Ibrutinib For research use only.

Ibrutinib

Synonyms: PCI-32765

Ibrutinib is a potent and highly selective Brutons tyrosine kinase (Btk) inhibitor with IC50 of 0.5 nM in cell-free assays, modestly potent to Bmx, CSK, FGR, BRK, HCK, less potent to EGFR, Yes, ErbB2, JAK3, etc. Ibrutinib is applicable as a Btk ligand in the synthesis of a series of PROTACs including P13I.

Ibrutinib Chemical Structure

Ibrutinib Chemical Structure

CAS: 936563-96-1

Selleck's Ibrutinib has been cited by 531 publications

Purity & Quality Control

Batch: Purity: 99.98%
99.98

Products often used together with Ibrutinib

Acalabrutinib (ACP-196)

Acalabrutinib (ACP-196) and Ibrutinib form a covalent bond with a cysteine residue (Cys481) in the BTK active site, leading to inhibition of BTK enzymatic activity. They are used as anti-neoplastic agents

Zanubrutinib

Both BTKi inhibitors treatment normalises lymphocyte subset frequency and reduces PD-1 expression on T cells.

Venetoclax (ABT-199)

Combined treatment leads to decrease in MCL1 protein and gives a synergistic effect

Jain N, et al. N Engl J Med. 2019 May 30;380(22):2095-2103.

Olaparib (AZD2281)

Ibrutinib plus olaparib additively inhibits MCL cell culture growth and impacts both cell survival and cell cycle regulation

Curtis AD, et al. Cancer Research. Vol. 77. 615 AMER ASSOC CANCER RESEARCH, 2017.

Osimertinib (AZD9291)

Ibrutinib reverses IL-6-induced osimertinib resistance via inhibition of Laminin α5/FAK signaling

Li L, et al. Commun Biol. 2022 Feb 23;5(1):155.

Related compound libraries

Choose Selective Target Protein Ligand Inhibitors

Cell Data

Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
human Rec1 cells Function assay 2.5 μM 6 h Inhibition of Lyn phosphorylation in human Rec1 cells at 2.5 uM incubated for 6 hrs by Western blotting method 25222877
human WSU-NHL cells Cytotoxic assay 72 h Cytotoxicity against human WSU-NHL cells assessed as growth inhibition after 72 hrs by CellTiter-Glo luminescent cell viability assay, IC50=1.09 μM 24915291
human SU-DHL6 cells Cytotoxic assay 72 h Cytotoxicity against human SU-DHL6 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo luminescent cell viability assay, IC50=0.58 μM. 24915291
human DOHH2 cells Cytotoxic assay 72 h Cytotoxicity against human DOHH2 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo luminescent cell viability assay, IC50=0.41 μM. 24915291
Sf9 cells Function assay 1 h Inhibition of LYN-A expressed in Sf9 cells after 60 mins by TR-FRET Assay, IC50=0.2 μM. 21958547
human Ramos cells Function assay 1 h Inhibition of Btk in human Ramos cells assessed as inhibition of PLC-gamma2 phosphorylation at Tyr1217 after 1 hr by Western blot analysis, IC50=14 nM. 24915291
human Pfeiffer cells Function assay 72 h Cytotoxicity against human Pfeiffer cells assessed as growth inhibition after 72 hrs by CellTiter-Glo luminescent cell viability assay, IC50=2 nM. 24915291
Sf9 cells Function assay 1 h Inhibition of human full-length BTK expressed in Sf9 cells using FAM-Srctide peptide as substrate after 60 mins by TR-FRET Assay， IC50=0.5 nM. 21958547
Sf9 insect cells Function assay 60 mins IC50 = 0.0003 μM 29146136
sf9 cells Function assay IC50 = 0.0003 μM 27994736
Sf9 insect cells Function assay 60 mins IC50 = 0.00034 μM 27912175
Sf9 insect cells Function assay 60 mins IC50 = 0.00034 μM 28432946
Sf9 insect cells Function assay 60 mins IC50 = 0.00034 μM 27956037
Sf9 cells Function assay 60 mins IC50 = 0.0004 μM 30006143
Sf9 cells Function assay 60 mins IC50 = 0.0005 μM 21958547
Ramos cells Function assay 1 h IC50 = 0.0005 μM 28280261
Sf9 cells Function assay 60 mins IC50 = 0.001 μM 30077608
Pfeiffer cells Cytotoxicity assay 72 h GI50 = 0.002 μM 24915291
B cells Function assay 1 h IC50 = 0.0046 μM 30290988
Sf9 insect cells Function assay 2 to 60 mins Ki = 0.0048 μM 28315597
Ramos cells Function assay 1 h IC50 = 0.0075 μM 24915291
Sf9 insect cells Function assay 60 mins IC50 = 0.008 μM 28315597
TMD8 cells Antiproliferative activity assay 72 h IC50 = 0.01 μM 29715023
CD19+ B cells Function assay 1 h IC50 = 0.012 μM 29457982
Sf9 insect cells Function assay 60 mins IC50 = 0.012 μM 28315597
Ramos cells Function assay 1 h IC50 = 0.014 μM 24915291
Sf9 insect cells Function assay 1 h IC50 = 0.0144 μM 29715023
Sf9 insect cells Function assay 60 mins IC50 = 0.0161 μM 29146136
HCC827 cells Antiproliferative activity assay 72 h IC50 = 0.039 μM 28734581
PC9 cells Function assay 72 h GI50 = 0.05 μM 28282122
Sf9 cells Function assay 60 mins IC50 = 0.1 μM 30006143
H3255 cells Function assay 72 h GI50 = 0.11 μM 28282122
BaF3 cells Function assay 72 h GI50 = 0.12 μM 26630553
BAF3 cells Antiproliferative activity assay 72 h GI50 = 0.12 μM 28956923
Sf9 insect cells Function assay 60 mins IC50 = 0.123 μM 28315597
Sf9 insect cells Function assay 60 mins IC50 = 0.146 μM 28315597
BAF3 cells Function assay 72 h GI50 = 0.16 μM 28282122
Sf9 cells Function assay 60 mins IC50 = 0.2 μM 21958547
MV411 cells Growth inhibition assay GI50 = 0.25 μM 28315597
MV4-11 cells Antiproliferative activity assay 72 h GI50 = 0.33 μM 26630553
MV4-11 cells Antiproliferative activity assay 72 h GI50 = 0.33 μM 28956923
DOHH2 cells Cytotoxicity assay 72 h GI50 = 0.41 μM 24915291
HCC827 cells Antiproliferative activity assay 96 h EC50 = 0.45 μM 28853575
SU-DHL6 cells Cytotoxicity assay 72 h GI50 = 0.58 μM 24915291
M07e cells Growth inhibition assay GI50 = 0.59 μM 28315597
NCI-H1975 cells Antiproliferative activity assay 96 h EC50 = 0.64 μM 28853575
SU-DHL-2 cells Growth inhibition assay GI50 = 0.64 μM 28315597
HEK293T cells Function assay 1 h IC50 = 0.9 μM 28280261
Ramos cells Antiproliferative activity assay 72 h IC50 = 0.92 μM 29715023
BA/F3 cells Antiproliferative activity assay 72 h IC50 = 1 μM 26258521
WSU-NHL cells Cytotoxicity assay 72 h GI50 = 1.09 μM 24915291
NCI-H1975 cells Function assay 72 h GI50 = 1.2 μM 28282122
NCI-H1975 cells Antiproliferative activity assay 72 h IC50 = 1.27 μM 28734581
Raji cells Antiproliferative activity assay 48 h IC50 = 1.49 μM 29567295
Pfeiffer cells Growth inhibition assay GI50 = 1.6 μM 28315597
A431 cells Antiproliferative activity assay 96 h EC50 = 2.38 μM 28853575
BAF3 cells Antiproliferative activity assay 72 h GI50 = 2.5 μM 28956923
U937 cells Growth inhibition assay GI50 = 2.9 μM 28315597
NB4 cells Growth inhibition assay GI50 = 3 μM 28315597
Ramos cells Growth inhibition assay GI50 = 3.4 μM 28315597
SKM1 cells Growth inhibition assay GI50 = 3.6 μM 28315597
U2932 cells Growth inhibition assay GI50 = 4.4 μM 28315597
Ramos cells Antiproliferative activity assay 72 h IC50 = 5.14 μM 30006143
Ramos cells Antiproliferative activity assay 48 h IC50 = 5.14 μM 27956037
Ramos cells Antiproliferative activity assay 48 h IC50 = 5.88 μM 28432946
Ramos cells Antiproliferative activity assay 72 h IC50 = 6.62 μM 29146136
K562 cells Antiproliferative activity assay 48 h IC50 = 7.5 μM 30077608
HL60 cells Antiproliferative activity assay 48 h IC50 = 8 μM 30077608
Ramos cells Antiproliferative activity assay 48 h IC50 = 8.11 μM 27994736
Ramos cells Antiproliferative activity assay 48 h IC50 = 8.26 μM 29567295
OCI-AML3 cells Growth inhibition assay GI50 = 9.2 μM 28315597
BAF3 cells Cytotoxicity assay 72 h GI50 = 10 μM 26630553
BAF3 cells Antiproliferative activity assay 72 h GI50 = 10 μM 28956923
BAF3 cells Growth inhibition assay 72 h GI50 = 10 μM 28282122
NAMALWA cells Antiproliferative activity assay 72 h IC50 = 10.45 μM 29146136
Ramos cells Antiproliferative activity assay 48 h IC50 = 12.6 μM 27912175
Raji cells Antiproliferative activity assay 48 h IC50 = 14.2 μM 30077608
Raji cells Antiproliferative activity assay 48 h IC50 = 15.2 μM 27994736
MIAPaCa2 cells Cytotoxicity assay 3 days IC50 = 16.6 μM 27077228
HeLa cells Cytotoxicity assay 3 days IC50 = 16.8 μM 27077228
Raji cells Antiproliferative activity assay 48 h IC50 = 19.3 μM 27912175
Raji cells Antiproliferative activity assay 48 h IC50 = 19.3 μM 28432946
Raji cells Antiproliferative activity assay 72 h IC50 = 19.5 μM 30006143
Raji cells Antiproliferative activity assay 48 h IC50 = 19.5 μM 27956037
NAMALWA cells Antiproliferative activity assay 72 h IC50 = 19.6 μM 30006143
A2780 cells Cytotoxicity assay 3 days EC50 = 20.1 μM 27077228
Raji cells Antiproliferative activity assay 72 h IC50 = 20.88 μM 29146136
A549 cells Antiproliferative activity assay 72 h IC50 = 21.79 μM 28734581
SW480 cells Cytotoxicity assay 3 days IC50 = 25.6 μM 27077228
Ramos cells Cytotoxicity assay 24 h IC50 = 28.7 μM 28274675
Click to View More Cell Line Experimental Data

Biological Activity

Description Ibrutinib is a potent and highly selective Brutons tyrosine kinase (Btk) inhibitor with IC50 of 0.5 nM in cell-free assays, modestly potent to Bmx, CSK, FGR, BRK, HCK, less potent to EGFR, Yes, ErbB2, JAK3, etc. Ibrutinib is applicable as a Btk ligand in the synthesis of a series of PROTACs including P13I.
Targets
BTK [1]
(Cell-free assay)		 BLK [1]
(Cell-free assay)		 Bmx [1]
(Cell-free assay)		 CSK [1]
(Cell-free assay)		 FGR [1]
(Cell-free assay)		 Click to View More Targets
0.5 nM 0.5 nM 0.8 nM 2.3 nM 2.3 nM
In vitro
In vitro

Ibrutinib shows the potent and irreversible inhibitory effect and selectivity for Btk enzymatic activity. In BCR pathway-activated DOHH2 cell line, Ibrutinib inhibits autophosphorylation of Btk, phosphorylation of Btk's physiological substrate PLCγ, and phosphorylation of further downstream kinase, ERK with IC50 of 11 nM, 29 nM and 13 nM, respectively. [1] Ibrutinib exhibits a significant dose-dependent and time-dependent induction of cytotoxicity in chronic lymphocytic leukemia (CLL) cells. In addition, Ibrutinib induces cell death depending on caspase pathway activation and antagonizes the ability of CLL cells to proliferate after TLR signaling. [2] A recent study shows that Ibrutinib inhibits BCR-activated primary B cell proliferation with IC50 of 8 nM and results in inhibition of TNFα, IL-1β and IL-6 production in primary monocytes with IC50 of 2.6 nM, 0.5 nM and 3.9 nM, respectively. [3]
Kinase Assay Kinase Assays
In vitro kinase IC50 values are measured using 33P filtration binding assay after 1 hour incubation of kinase, 33P-ATP, Ibrutinib, and substrate [0.2 mg/mL poly(EY)(4:1]. Assays are performed at Reaction Biology.
Cell Research Cell lines Chronic lymphocytic leukemia (CLL) cells
Concentrations 0.01-100 μM
Incubation Time 48 hours
Method

MTT (3'[4,5-dimethylthiazol-2-yl]-2,5-diphenyl-tetrazolium bromide) assays are performed to determine cytotoxicity. Briefly, cells (CLL B cells or healthy volunteer T cells or NK cells) are incubated for 48 hours with different concentrations of Ibrutinib, or vehicle control. MTT reagent is then added, and plates are incubated for an additional 20 hours before washing with protamine sulfate in phosphate-buffered saline. Dimethyl sulfoxide is added, and absorbance is measured by spectrophotometry at 540 nm in a Labsystems plate reader. Cell viability is also measured at various time points with the use of annexin/PI flow cytometry. Data are analyzed with Expo-ADC32 software package. Results are expressed as the percentage of total positive cells over untreated control. Experiments examining caspase-dependent apoptosis includes the addition of 100μM Z-VAD.
Experimental Result Images Methods Biomarkers Images PMID
Western blot pEGFR(Tyr1068) / EGFR pBTK / pPLCγ2 / pAKT / pERK / pJNK 28061447
Immunofluorescence CD11b COX-2 30231870
ELISA hTNFα IL-10 26627823
In Vivo
In vivo

In a collagen-induced arthritis model, Ibrutinib significantly reduces clinical arthritis scores reflecting paw swelling and joint inflammation by inhibiting B-cell activation. In a MRL-Fas(lpr) lupus model, Ibrutinib reduces renal disease and autoantibody production. [1] In an adoptive transfer TCL1 mouse model of CLL, Ibrutinib (25 mg/kg/day) causes a transient early lymphocytosis, and delays CLL disease progression. [4]
Animal Research Animal Models MRL-Fas(lpr) lupus model and collagen-induced arthritis model.
Dosages ≤50 mg/kg
Administration Administered via p.o.
NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT06084923 Not yet recruiting Chronic Lymphocytic Leukemia Gruppo Italiano Malattie EMatologiche dell''Adulto December 2023 --
NCT05694312 Recruiting Autoimmune Hemolytic Anemia|Chronic Lymphocytic Leukemia|Small Lymphocytic Lymphoma|Monoclonal B-Cell Lymphocytosis CLL-Type Gruppo Italiano Malattie EMatologiche dell''Adulto November 24 2023 Phase 2
NCT05782374 Recruiting PCNSL IRCCS San Raffaele August 10 2022 --
NCT05105841 Active not recruiting Chronic Lymphocytic Leukemia (CLL)|Small Lymphocytic Lymphoma (SLL) AbbVie November 8 2021 Phase 2

Chemical lnformation & Solubility

Molecular Weight 440.5 Formula

C25H24N6O2
CAS No. 936563-96-1 SDF Download Ibrutinib SDF
Smiles C=CC(=O)N1CCCC(C1)N2C3=NC=NC(=C3C(=N2)C4=CC=C(C=C4)OC5=CC=CC=C5)N
Storage (From the date of receipt)

In vitro
Batch:

DMSO : 88 mg/mL ( (199.77 mM)； Moisture-absorbing DMSO reduces solubility. Please use fresh DMSO.)

Ethanol : 8 mg/mL

Water : Insoluble


Molecular Weight Calculator

In vivo
Batch:

Add solvents to the product individually and in order.


In vivo Formulation Calculator

Preparing Stock Solutions

Molarity Calculator

Mass Concentration Volume Molecular Weight

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.

Frequently Asked Questions

Question 1:
How to reconstitute the compound S2680 for in vivo studies?

Answer:
For in vivo study, we suggest to use 5% DMSO+30% PEG 300+5% Tween 80+ddH2O up to 10mg/ml.

Tags: buy Ibrutinib | Ibrutinib supplier | purchase Ibrutinib | Ibrutinib cost | Ibrutinib manufacturer | order Ibrutinib | Ibrutinib distributor